For adjunctive use in adults age 22+ on ADT1

Tap into the brain’s power to take on MDD symptoms1

Rejoyn is the first and only prescription app for the treatment of MDD symptoms. It is a 6-week adjunctive treatment authorized by the FDA.1,2

ADT=antidepressant therapy; MDD=major depressive disorder.

Meet Rejoyn

Rejoyn, when used alongside ADT, can treat MDD symptoms differently.1,2

Image
Poster image from video content of a person doing a brain-training exercise in Rejoyn

Rejoyn is designed to improve emotion regulation and processing
through 2 core components1:

Image
Icon of a play button inside of a rectangular frame

Cognitive behavioral therapy (CBT)-based video lessons

Image
Sample screen of the Rejoyn app. The on-screen text displays "What to expect" and "Your tasks". The Rejoyn character is on the left with the text "Therapeutic Lesson". The right has an image of a smiling person with the text "Brain Exercise".
Image
Icon of a brain with two dots that are connected

Cognitive-emotional training (CET) exercises

LEARN MORE

Clinically demonstrated efficacy and safety1

The Mirai clinical trial evaluated the effectiveness and safety of Rejoyn as an adjunct to ADT in patients with MDD, compared with a cognitive-training control, or Sham. Patients treated with Rejoyn experienced1:

  • Reduced MDD symptoms1
  • Zero adverse events related to Rejoyn1

REVIEW THE DATA

Including detailed safety information.

High adherence and satisfaction rates1

  • 88.1% of patients using Rejoyn adhered to treatment in
    the clinical trial, defined as completing at least 12
    of the 18 treatment sessions.1
  • 76%of patients using Rejoyn reported that they were “extremely satisfied” (37.1%) or “satisfied” (38.9%) with the experience.1

An app, prescribed like a pill1

Learn how to provide Rejoyn to the patients in your practice.

Frequently asked questions

Unlike wellness apps, the Rejoyn app is in a class of software-based treatments called prescription digital therapeutics (PDTs). Rejoyn is regulated by the FDA and requires a prescription from a healthcare professional.2

There are 2 ways to prescribe Rejoyn: e-prescribe or refer for a virtual consult. If you are a licensed prescriber, you can prescribe Rejoyn through your electronic health record system. If you are a behavioral health clinician, you can refer patients for a virtual consult on the patient website.

Whether you e-prescribe or refer for a virtual consult, a patient's prescription will be sent directly to BlinkRx—this is the online pharmacy that dispenses access codes for Rejoyn.

Licensed prescribers can learn how to find BlinkRx in the electronic medical record here.

BlinkRx is an online pharmacy that specializes in digital products and dispenses Rejoyn. You can call 1-833-Y-REJOYN (1-833-973-5696) Monday through Friday, 8 AM to 8 PM ET, excluding holidays, and select from a list of menu options that will connect you to BlinkRx.

A patient's prescription will be sent directly to BlinkRx for processing, payment, and fulfillment.

  • BlinkRx will follow up with your patient to collect payment. Please note that insurance providers may not cover prescription digital therapeutics. As a medical device, Rejoyn is reimbursable by HSA/FSA
  • Once payment has been received, the pharmacy will text and email your patient within 24 to 48 hours with an access code for Rejoyn
  • Your patient can download the Rejoyn app, set up their profile, and enter their access code to unlock treatment

FSA=flexible spending account; HSA=health savings account.

Image
Icon of a person with a medical symbol

End-to-end nurse support

Patients can call the nurse support line at 1-833-Y-REJOYN (1-833-973-5696) for assistance throughout their 6-week treatment with Rejoyn. Available Monday through Friday, 8 AM to 8 PM ET, excluding holidays.

Where to find Rejoyn

INDICATION: Rejoyn is a prescription digital therapeutic for the treatment of Major Depressive Disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. It is intended to reduce MDD symptoms.

SAFETY INFORMATION: Rejoyn is not intended to be used as a standalone therapy or a substitute for medication. Patients should continue their current treatment as directed.

Rejoyn does not monitor the patient's symptoms or clinical status and cannot send or receive alerts or warnings to the prescriber. Patients should be clearly instructed that if they believe their depression is worsening or if they have feelings or thoughts of harming themselves or others, to contact a healthcare professional, dial 911 or go to the nearest emergency room immediately.

The Apple logo is a trademark of Apple Inc., registered in the United States and other countries. App Store is a service mark of Apple Inc., registered in the United States and other countries. Google Play and the Google Play logo are trademarks of Google LLC.